Department of Cancer Biology & Pharmacology, University of Illinois College of Medicine at Peoria, 1 Illini Drive, Peoria, IL 61605, USA.
Pharmacogenomics. 2011 Apr;12(4):535-46. doi: 10.2217/pgs.10.207.
Non-small-cell lung carcinoma demonstrated considerable variability in its chemoresponse. However, the prospect of individualized medicine holds high hopes for improving patient survival. The study of tumor and patient genetic profiles, relative to drug-related genes, may offer new opportunities for tailoring treatments. Matrix metalloproteinases (MMPs) are zinc-containing endopeptidases, which degrade the extracellular matrix and basement membrane, and process bioactive mediators involved in promoting aspects of tumor growth. Polymorphisms in MMP genes known to influence the protein-expression patterns has been shown to influence therapy outcomes by altering signaling pathways. In this article, we address the polymorphic association of MMPs in response to chemotherapy in non-small-cell lung carcinoma. Advances in genome technology and their comprehensive and systematic deployment to elucidate the genomic basis of MMP differences promise to ultimately enhance the efficacy of chemotherapy while reducing its toxicity for the treatment of various cancers.
非小细胞肺癌在化疗反应方面表现出相当大的变异性。然而，个体化医疗的前景为提高患者生存率带来了很高的期望。研究肿瘤和患者的遗传特征，相对于与药物相关的基因，可能为定制治疗提供新的机会。基质金属蛋白酶（MMPs）是含有锌的内肽酶，可降解细胞外基质和基底膜，并处理生物活性介质，促进肿瘤生长的各个方面。已知影响蛋白表达模式的 MMP 基因多态性已被证明通过改变信号通路影响治疗结果。在本文中，我们探讨了 MMP 在非小细胞肺癌化疗反应中的多态性关联。基因组技术的进步及其全面系统的部署，以阐明 MMP 差异的基因组基础，有望最终提高化疗的疗效，同时降低其治疗各种癌症的毒性。
